Axi-cel demonstrated significant clinical benefit as a first-line treatment for patients with high-risk large B-cell lymphoma.
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
Response appears to be consistent across histological subtypes.
A multicenter, retrospective study demonstrated higher PFS and OS rates with allogeneic transplant for relapsed/refractory TCL.
The addition of romidepsin to CHOP did not improve PFS over CHOP alone among patients with previously untreated PTCL.
The purpose of this study was to evaluate azacitidine in combination with CHOP in a PTCL population enriched for AITL.